SciBase International Melanoma Pivotal Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01077050|
Recruitment Status : Completed
First Posted : February 26, 2010
Results First Posted : December 30, 2013
Last Update Posted : December 30, 2013
The purpose of this clinical investigation was to determine the safety and effectiveness of the SciBase III device (Test) designed to help distinguish between malignant melanoma and benign lesions, using electrical impedance spectroscopy (EIS) relative to the histological gold standard (Reference).
The purpose of the study is to collect data to support a Pre-market Application(PMA) to obtain Food and Drug Administration(FDA) approval to market the SciBase III Electrical Impedance Spectrometer.
|Condition or disease||Intervention/treatment||Phase|
|Malignant Melanoma||Device: SciBase III Electrical Impedance Spectrometer||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1951 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||SciBase International Melanoma Pivotal Study|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||September 2011|
|Actual Study Completion Date :||October 2011|
Subjects with suspected malignant melanoma or lesions designated for total excision were included into the study. To ensure no selection bias, all eligible lesions from a subject were included into the study. All study eligible skin lesion(s) were examined with the investigational device, photographed and removed by an excisional biopsy.
Device: SciBase III Electrical Impedance Spectrometer
SciBase III Electrical Impedance Spectrometer is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Enrolled subject will undergo skin measurements with SciBase III Electrical Impedance Spectrometer. The relevant skin lesion(s) will be excised and diagnosed as per routine treatment.
- SciBase Sensitivity and Specificity [ Time Frame: Post data lock ]
This study has two co-primary objectives, aiming to demonstrate the accuracy of SciBase device:
- Sensitivity ≥ 0.90 to detect Melanoma
- Sensitivity - (1-Specificity) > 0.00
Sensitivity is the proportion of correctly identified cases of Melanoma. Specificity is the proportion of correctly identified cases of non-melanoma.
- Sensitivity and Specificity [ Time Frame: Post data lock ]
Secondary confirmatory objective included two co-secondary endpoints that were defined similarly to the co-primary endpoints, but used the Secondary definition of dichotomous reference diagnosis.
Positive Reference Diagnosis: Melanoma, Squamous Cell Carcinoma, Basal Cell Carcinoma, Severe Dysplastic Nevus (High grade dysplasia)
Negative Reference Diagnosis: All other skin lesions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01077050
|United States, Arizona|
|University of Arizona|
|Tucson, Arizona, United States, 85719|
|Sahlgrenska University Hospital|
|Gothenburg, Sweden, 41345|
|Study Director:||Ulrik H Birgersson, PhD||SciBase and Karolinska Institutet|